Products
Belantamab Mafodotin Biosimilar Antibody-Drug Conjugate (BCMA) for Research
Pre-made Belantamab Mafodotin benchmark antibody (Whole mAb ADC, anti-TNFRSF17 therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-752-1mg | 1mg | 4635 |
| GMP-Bios-INN-752-10mg | 10mg | |
| GMP-Bios-INN-752-100mg | 100mg | |
| GMP-Bios-INN-752-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Belantamab Mafodotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody Drug Conjugate |
| INN Name | Belantamab Mafodotin |
| Target | TNFRSF17 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | GlaxoSmithKline (Brentford UK) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - TNFRSF17
1. Protein Tumor necrosis factor receptor superfamily member 17
2. Gene TNFRSF17
3. Organism Homo sapiens (Human)
Function
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK.
